New drugs in non-small cell lung cancer. An overview
- 30 April 1995
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 12, S155-S162
- https://doi.org/10.1016/0169-5002(95)00431-y
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Phase II Study of Taxol, Merbarone, and Piroxantrone in Stage IV Non-Small-Cell Lung Cancer: The Eastern Cooperative Oncology Group ResultsJNCI Journal of the National Cancer Institute, 1993
- Cell-signaling targets for antitumour drug developmentCancer Chemotherapy and Pharmacology, 1993
- Clinical and preclinical activity of 2′,2′- difluorodeoxycytidine (gemcitabine)Cancer Treatment Reviews, 1993
- DNA topoisomerase-trapping antitumour drugsEuropean Journal Of Cancer, 1992
- Improved Therapeutic Index by Leucovorin of Edatrexate, Cyclophosphamide, and Cisplatin Regimen for Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1992
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 1991
- A Phase II Study of Navelbine (Vinorelbine) in the Treatment of Non-Small-Cell Lung CancerAmerican Journal of Clinical Oncology, 1991
- Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubulesInternational Journal of Cancer, 1990
- Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancerInvestigational New Drugs, 1990
- DNA TOPOISOMERASESAnnual Review of Biochemistry, 1985